Maravai unit TriLink opens GMP enzyme manufacturing facility in Florida expansion
Maravai Lifesciences Holdings, Inc. Class A
Maravai Lifesciences Holdings, Inc. Class A MRVI | 0.00 |
- Maravai LifeSciences opened a GMP enzyme manufacturing facility in Jupiter, Florida, expanding integrated IVT supply from R&D through commercial scale.
- Site adds cleanrooms, validated processes, scalable capacity, full traceability to meet regulatory requirements across major markets.
- First commercial GMP enzyme batch shipped in June 2026, signaling readiness for commercial-scale supply to RNA therapeutics developers.
- Flagship GMP CleanScribe RNA Polymerase targets up to 85% lower dsRNA formation versus wild-type T7, aiming to improve mRNA purity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260616862149) on June 16, 2026, and is solely responsible for the information contained therein.
